Compare IDXX & IQV Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | IDXX | IQV |
|---|---|---|
| Founded | 1983 | 1982 |
| Country | United States | United States |
| Employees | N/A | 93000 |
| Industry | Biotechnology: In Vitro & In Vivo Diagnostic Substances | Biotechnology: Commercial Physical & Biological Resarch |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 45.4B | 43.1B |
| IPO Year | 1996 | 2013 |
| Metric | IDXX | IQV |
|---|---|---|
| Price | $521.51 | $273.27 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 9 | 16 |
| Target Price | ★ $721.67 | $227.13 |
| AVG Volume (30 Days) | 428.9K | ★ 1.3M |
| Earning Date | 05-05-2026 | 05-05-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 22.59 | 4.67 |
| EPS | ★ 7.74 | 1.61 |
| Revenue | $4,303,702,000.00 | ★ $9,739,000,000.00 |
| Revenue This Year | $10.88 | $6.77 |
| Revenue Next Year | $8.59 | $5.89 |
| P/E Ratio | ★ $67.38 | $167.76 |
| Revenue Growth | 10.42 | ★ 41.60 |
| 52 Week Low | $500.61 | $154.50 |
| 52 Week High | $769.98 | $273.88 |
| Indicator | IDXX | IQV |
|---|---|---|
| Relative Strength Index (RSI) | N/A | N/A |
| Support Level | N/A | N/A |
| Resistance Level | N/A | N/A |
| Average True Range (ATR) | 0.00 | 0.00 |
| MACD | 0.00 | 0.00 |
| Stochastic Oscillator | 0.00 | 0.00 |
Idexx Laboratories primarily develops, manufactures, and distributes diagnostic products, equipment, and services for pets and livestock. Its key product lines include single-use canine and feline test kits that veterinarians can employ in the office, benchtop chemistry and hematology analyzers for test-panel analysis on-site, reference lab services, and tests to detect and manage disease in livestock. The firm also offers vet practice management software and consulting services to animal hospitals. Idexx derives roughly 35% of its revenue from outside the United States.
Iqvia is a global leader in clinical research and technology solutions for the life science industry. Formed in 2016 from the merger of Quintiles and IMS Health, it combined clinical trial services with extensive healthcare data and analytics. Its research and development solutions segment provides outsourced clinical development services spanning drug discovery, trial design, patient recruitment, site management, clinical testing, real-world studies, and the regulatory approval process. Its commercial solutions segment helps companies optimize product commercialization through analytics, technology, and outsourced sales and medical services. Together, Iqvia supports customers across the life science industry, and it serves biopharmaceutical firms, providers, payers, and policymakers.